Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach.
Levosimendan
cardiopulmonary exercise test
heart failure
Journal
Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
04
08
2021
revised:
21
09
2021
accepted:
12
10
2021
pubmed:
12
11
2021
medline:
4
5
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
In advanced heart failure (HF), levosimendan increases peak oxygen uptake (VO Twenty patients hospitalized for advanced HF underwent, before and shortly after levosimendan infusion, 2 different cardiopulmonary exercise tests: (a) a personalized ramp protocol with repeated arterial blood gas analysis and standard spirometry including alveolar-capillary gas diffusion measurements at rest and at peak exercise, and (b) a step incremental workload cardiopulmonary exercise testing with continuous near-infrared spectroscopy analysis and cardiac output assessment by bioelectrical impedance analysis.Levosimendan significantly decreased natriuretic peptides, improved peak VO In advanced HF, levosimendan increases peak VO
Sections du résumé
BACKGROUND
In advanced heart failure (HF), levosimendan increases peak oxygen uptake (VO
METHODS AND RESULTS
Twenty patients hospitalized for advanced HF underwent, before and shortly after levosimendan infusion, 2 different cardiopulmonary exercise tests: (a) a personalized ramp protocol with repeated arterial blood gas analysis and standard spirometry including alveolar-capillary gas diffusion measurements at rest and at peak exercise, and (b) a step incremental workload cardiopulmonary exercise testing with continuous near-infrared spectroscopy analysis and cardiac output assessment by bioelectrical impedance analysis.Levosimendan significantly decreased natriuretic peptides, improved peak VO
CONCLUSIONS
In advanced HF, levosimendan increases peak VO
Identifiants
pubmed: 34763079
pii: S1071-9164(21)00435-8
doi: 10.1016/j.cardfail.2021.10.009
pii:
doi:
Substances chimiques
Hemoglobins
0
Simendan
349552KRHK
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-514Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest None declared.